Natera Inc. has announced that new data on its Signatera™ test will be presented at the 2025 American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The presentations will highlight the clinical validity and utility of Signatera in hematologic malignancies, including aggressive and indolent lymphomas and multiple myeloma. Key findings to be presented suggest that Signatera detected recurrence prior to imaging and outperformed standard surveillance methods. Additionally, personalized circulating tumor DNA (ctDNA) detection was found to be a strong predictor of clinical outcomes, and Signatera helped clarify ambiguous imaging results. The data also support the use of Signatera as a response assessment tool in lymphoma, and ctDNA-measurable residual disease was incorporated into the NCCN Guidelines for diffuse large B-cell lymphoma in January 2025. The results will be presented in oral and poster sessions during the meeting.